One cool thing about the United States is that there are more people whose job is to deny healthcare coverage without having any medical background than there are people to provide healthcare coverage and they’ve somehow convinced people that the doctors are where the monetary waste is happening

Dr. Brian Gantwerker 🟧 🟦 🇮🇱@cscla.medsky.social · last yr.

#medsky if an insurer is making a “determination if something is medically necessary”, how is it not a medical decision and therefore practicing medicine?

It was an honor to present alongside these two esteemed physician-scientists who have pushed the frontiers of transplantation and cell therapy for patients with autoimmune disorders. #Tandem25 www.tandemmeetingsnews.com/experts-trac...

Experts trace work to treat autoimmune disorders - Tandem Meetings News

Keith Sullivan, MD, and others discussed progress with transplantation and cell therapy for autoimmune diseases.

tandemmeetingsnews.com

Something you don't see every day! Digitizing the human proteome in >53,000 individuals with 15-year follow-up and, with machine learning, unraveling nearly 500 disease-causing proteins www.cell.com/cell/fulltex... open-access

Happy Holidays！💐 Credit to: Dario Brunetti

If you want to understand why healthcare pricing is horrific, the first thing to know is that our system puts 100% of the credit risk for deductibles, copays and co-insurance on hospitals and doctors. That's insane. We have turned them into Sub Prime Lenders 🧵

Happy holidays from the Duke Rheum crew ❄️ ⛄️ 🎄 @mithurheum.bsky.social

There is a human tissue that builds itself up and breaks itself down every 28 days (on average) using non-scarring wound healing and instead of studying that and learning everything we can about it we think it's gross and look for other less relevant models to understand wound healing.

The MITIGATE trial of inebilizumab (aCD19 mAb) for IgG4-RD should get us thinking about which rheumatologic diseases do/don’t warrant deep B cell depletion (i.e. CAR Ts) ⬇️ flares ⬆️ GC-free remission (note rapid steroid taper in placebo group) ⬆️ infections & cytopenias www.nejm.org/doi/full/10....

Inebilizumab for Treatment of IgG4-Related Disease | NEJM

IgG4-related disease is a multiorgan, relapsing, fibroinflammatory, immune-mediated disorder with no approved therapy. Inebilizumab targets and depletes CD19+ B cells and may be effective for treat...

nejm.org

🆕 #ACR24 | Updated Guidelines for Lupus Nephritis Treatment & Management 🫘 Highlights 🔶 • Critical role of renal biopsy • Differences for treatment by LN Class • Adjunctive Rx w/ HCQ & RAASi • GC pulse ⇢ *moderate/low* dose PDN #Lupus #NephSky #RheumSky #Rheumatology #MedSky

It was a wonderful #ACR24 and I am truly honored to have received the Distinguished Fellow Award from the American College of Rheumatology this year

Mithu Maheswaranathan, MD@mithurheum.bsky.social · 2y ago

Congratulations to @sjbracken.bsky.social & all the ACR Distinguished Fellow award recipients at #ACR24 🥇 Anyone who knows Sonali knows how dedicated and hardworking she is — from her research to patient care — working to improve the lives of patients with #scleroderma! #DukeRheum

First-of-its kind evidence in severe dSSc demonstrates that CD19 CAR T may both stabilize/improve: 🔶 Fibrotic organ dysfunction 🔶 Vascular dysfunction (as marked by ⬇️ in RP severity and digital ulcerations) 🔶 Grip strength, contractures, and hand function www.thelancet.com/journals/lan...